Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in  epidermal growth factor receptor  ( EGFR )-mutant non-small cell lung cancer (NSCLC)

Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

Giulio Metro, Angelo Bonaiti, Ilaria Birocchi, Francesca Marasciulo, Martina Ubaldi, Niccolò Metelli, Vincenzo Minotti, Alfredo Addeo